Pharmaceutical Regulatory Consulting: When You Need It and What It Costs

Most pharmaceutical companies don’t hire a regulatory consultant because they want to. They hire one because they’ve reached a point in their development programme where the regulatory complexity exceeds what their internal team can handle — or because they don’t have an internal team yet and need expert guidance to navigate a regulatory pathway they’ve never walked before.

Pharmaceutical regulatory consulting is a broad field. Understanding what it covers, when you actually need it, and what it realistically costs is the starting point for making a good decision.

What Is Pharmaceutical Regulatory Consulting?

Pharmaceutical regulatory consulting encompasses advisory and execution services that help drug developers, manufacturers, and marketers navigate the regulatory requirements for pharmaceutical products. In the EU context, this means the requirements set by the European Medicines Agency (EMA), national competent authorities (ANSM in France, BfArM in Germany, MHRA in the UK post-Brexit), and the legislative framework of Directive 2001/83/EC and its implementing regulations.

The scope of pharmaceutical regulatory consulting typically includes:

Regulatory strategy: Determining the optimal regulatory pathway for a product — which procedure to use for marketing authorisation, which member state to use as reference, which data package is needed, and what the realistic timeline and probability of success are.

Dossier preparation: Writing and compiling the Common Technical Document (CTD) — the standardised format for marketing authorisation applications in the EU, USA, Canada, Japan, and most other regulated markets. The CTD has five modules covering administrative information, summaries, quality (chemistry, manufacturing, and controls), non-clinical studies, and clinical studies.

Regulatory submissions: Managing the submission process — formatting, electronic submission, response to questions from regulatory authorities, and follow-up through to approval.

GMP compliance: Advising on Good Manufacturing Practice requirements for drug substance and drug product manufacturing, including preparation for regulatory inspections.

Pharmacovigilance: Setting up and managing pharmacovigilance systems, including the Pharmacovigilance System Master File (PSMF), periodic safety update reports (PSURs), and signal detection.

Lifecycle management: Managing post-approval changes, variations, renewals, and line extensions.

When Do You Need a Pharmaceutical Regulatory Consultant?

Scenario 1: First EU Marketing Authorisation Application

If your company is preparing its first EU marketing authorisation application, a regulatory consultant is almost always necessary. The CTD is a complex document — Module 3 (quality) alone can run to thousands of pages for a complex drug product. The procedural requirements, timelines, and question-response cycles require expertise that takes years to develop.

The cost of getting a first MAA wrong — a refusal, a major objection requiring additional studies, or a withdrawal and resubmission — typically far exceeds the cost of expert regulatory support from the outset.

Scenario 2: Entering the EU from a Non-EU Market

US and Canadian pharmaceutical companies entering the EU market face a regulatory framework that is structurally similar to FDA and Health Canada but differs in important details. The EU’s centralised procedure (through EMA) and decentralised/mutual recognition procedures have no direct FDA equivalent. The EU’s clinical trial requirements (EU CTR), pharmacovigilance obligations, and variation procedures all require specific EU expertise.

A regulatory consultant with EU-specific experience bridges this gap, translating the company’s existing regulatory knowledge into EU-specific strategy.

Scenario 3: Regulatory Crisis Management

When a regulatory authority raises a major objection, issues a non-compliance statement, or initiates a referral procedure, companies often need expert support that their internal team cannot provide. Regulatory consultants with specific experience in the relevant therapeutic area or regulatory procedure can provide the strategic and technical support needed to resolve the issue.

Scenario 4: Capacity Overflow

Established pharmaceutical companies with internal regulatory affairs teams sometimes face periods where the workload exceeds internal capacity — multiple simultaneous submissions, a major variation programme, or a post-merger integration. Regulatory consultants provide flexible capacity without the cost and commitment of permanent headcount.

What Does Pharmaceutical Regulatory Consulting Cost in Europe?

Costs vary significantly based on the consultant’s experience, the complexity of the work, and the engagement model.

Day Rates

Individual regulatory consultants in Europe typically charge:

• Junior consultant (3–7 years experience): €600–€1,000/day
• Senior consultant (7–15 years experience): €1,000–€1,800/day
• Principal/expert consultant (15+ years, former regulatory authority experience): €1,800–€3,500/day

Regulatory consulting firms typically charge 20–40% more than individual consultants for equivalent seniority, reflecting overhead, quality systems, and team support.

Project-Based Fees

For defined deliverables, project-based fees are common:

Service	Typical Fee Range
Regulatory strategy assessment	€5,000–€25,000
CTD Module 3 preparation (simple product)	€30,000–€80,000
CTD Module 3 preparation (complex product)	€80,000–€200,000+
Full MAA dossier preparation	€150,000–€500,000+
Variation application (minor)	€3,000–€10,000
Variation application (major)	€15,000–€50,000
GMP gap assessment	€8,000–€25,000
Pharmacovigilance system setup	€15,000–€40,000

These are indicative ranges. Actual costs depend heavily on the complexity of the product, the completeness of existing data, and the regulatory history of the product.

How to Select a Pharmaceutical Regulatory Consultant

Relevant Experience

Regulatory consulting is highly specialised. A consultant with deep experience in oncology biologics may not be the right choice for a traditional small molecule generics programme. Verify that the consultant has specific experience with:

• Your product type (small molecule, biologic, herbal, generic, etc.)
• Your regulatory pathway (centralised procedure, decentralised procedure, national procedure)
• Your target markets (EU, specific member states, UK post-Brexit)
• Your development stage (pre-IND, Phase I-III, MAA, post-approval)

Former Regulatory Authority Experience

Consultants who have worked at EMA, ANSM, BfArM, or other EU regulatory authorities bring insider knowledge of assessment processes, reviewer expectations, and common objection patterns. This experience is particularly valuable for complex applications or regulatory crisis situations.

References and Track Record

Ask for references from clients with similar products and regulatory situations. A consultant’s track record of successful approvals in your therapeutic area is the most reliable predictor of future performance.

Conflict of Interest

Regulatory consultants should not have conflicts of interest — for example, financial relationships with competing products or regulatory authorities. Ask explicitly about conflicts of interest and review the consultant’s policies.

The EU Regulatory Landscape: EMA vs. National Procedures

For pharmaceutical regulatory consulting in the EU, the choice of regulatory procedure is a strategic decision:

Centralised Procedure (CP): Mandatory for biotechnology products, ATMPs, orphan medicines, and certain other categories. Optional for other innovative products. Results in a single EU-wide marketing authorisation. Managed by EMA with assessment by a rapporteur and co-rapporteur member state.

Decentralised Procedure (DCP): For products not eligible for the centralised procedure. The applicant selects a Reference Member State (RMS) and Concerned Member States (CMS). The RMS leads the assessment; CMS can raise concerns. Results in national authorisations in all participating member states.

Mutual Recognition Procedure (MRP): For products already authorised in one EU member state. The existing national authorisation is recognised by other member states.

National Procedure: For products intended for a single member state only.

The choice of procedure affects timeline, cost, and strategic flexibility. A pharmaceutical regulatory consultant’s first deliverable is typically a regulatory strategy document recommending the optimal procedure and pathway.

At Care Europe, we provide pharmaceutical regulatory consulting for companies entering the EU market, with specific expertise in the French regulatory pathway (ANSM) and EU centralised procedure strategy. Contact us at [email protected].